ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more


Latest Posts
1 to 16 of 283 Posts
1 2 3 ... 18
Week In Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.
Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
Week In Review: China Life Science Announces $5 Billion In Deals, A Weekly Record
BeiGene, a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion The company is developing a portfolio of 25 candidates, with several of them in Phase III tests.
Week In Review: Ocumension Climbs To $2.5 Billion Market Cap After $184 Million Hong Kong IPO
Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. The company has raised $200 million in venture capital.
Week In Review: China Life Science Announces Deals Worth $1.3 Billion
Boehringer Ingelheim launched its External Innovation Hub China in Shanghai to increase the company's China R&D partnerships.. The Hub has $508 million to spend on China clinical research, expansion of production sites and research partnerships.
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
Week In Review: Six China Biopharma Deals Raise A Total Of $255 Million
Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. Miaoshou Doctor, an online-offline healthcare company headquartered in Beijing, closed an $85 million Series D1 round.
Week In Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration With Roche
Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Roche will have an option to license each product for ex-China development and commercialization.
Week In Review: China Life Science Companies Raise Nearly $1 Billion Led By Legend's $424 Million US IPO
In a successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60, giving Legend a market capitalization of nearly $5 billion.
Week In Review: Shenzhen's MGI Tech Raises $1 Billion To Develop Gene Sequencing Machines
MGI Tech of Shenzhen, a company making gene-sequencing machines and related equipment, completed a $1 billion Series B round led by IDG Capital and CPE. Suzhou Kintor Pharma completed a $240 million IPO on the Hong Kong Exchange.
Week In Review: CanSino Publishes Positive Data From Trial Of COVID-19 Vaccine
Tianjin CanSinoBIO published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination.
Week In Review: Sorrento Announces MAb Inhibits 100% Of SARS-CoV-2 Infection
Sorrento Therapeutics, a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor, after four days of incubation.
Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly
Junshi Biosciences out-licensed ex-China rights for a therapeutic antibody aimed at preventing and treating COVID-19 to Eli Lilly. Lilly plans to file an IND and start trials in the US in Q2 of 2020.
Week In Review: I-Mab Seeking $2 Billion Deal For CD-47 Candidate
I-Mab BioPharma of Shanghai is shipping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. I-Mab believes TJC4 is a potential global CD47 because it binds to a unique epitope on CD47.
Week In Review: Akeso Stages $335 Million HK IPO For Mono-/Bi-Specific Antibodies
AkesoBio of Zhongshan staged a $335 million Hong Kong IPO to support its novel mono- and bi-specific antibodies, and climbed 50% higher in its first trading session.
Week In Review: Leo Pharma Acquires Atopic Dermatitis Candidate From Taiwan-China Company In $570 Million Deal
Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai.
1 to 16 of 283 Posts
1 2 3 ... 18